Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety

Inclusion Criteria: Signed informed consent Male or female, age ≥ 18 years and ≤ 80 years at the time of signing informed consent. Report clinically significant symptoms of anxiety, defined as a score of 10 or greater on the Generalized Anxiety Disorder Scale, 7th edition (GAD-7) Ability and willingness to complete all study visits and procedures Agreement to engage with using the device on a daily basis Agreement to engage with trial mentors Agreement not to use prescription, or over the counter, anxiety medications for the duration of the trial Access to Wi-Fi Access to Apple smart phone (If not an Apple iPod will be supplied) Exclusion Criteria: History of skin breakdown, eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind the ears. Previous diagnosis of HIV infection or AIDS (HIV is known to cause a vestibular neuropathy which would prevent VeNS from working) Use of beta-blockers within 1 month of starting the study Use of antidepressants or unstable dose within 3 months of starting study Medication for anxiety (unless regime stable for last 3 months). A history of stroke or severe head injury (as defined by a head injury that required a craniotomy or endotracheal intubation). (In case this damaged the neurological pathways involved in vestibular stimulation). Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.). Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice) History of epilepsy History of active migraines with aura History of head injury requiring intensive care or neurosurgery History of cognitive impairment History of of bipolar, psychotic or substance use disorders Regular use (more than twice a month) of antihistamine medication within the last 6 months. History or presence of malignancy within the last year (except basal and squamous cell skin cancer and in-situ carcinomas) A diagnosis of myelofibrosis or a myelodysplastic syndrome. Previous use of Modius device Participation in other clinical trials sponsored by Neurovalens Participation in any other anxiety studies Have a member of the same household who is currently participating in this study. Not fluent in English language History of vestibular dysfunction or other inner ear disease